Brainstorm Cell (BCLI): Short-Term Debt to Equity Ratio
Brainstorm Cell (BCLI) is actively developing protocols for NurOwn therapy aimed at combating ALS, currently undergoing the regulatory approval stage. The business relies on synergy with specialized research centers to restore brain functions. Meanwhile, the R&D model is based on outsourced testing, and the indicator stands at 0.00. The financial price chart below demonstrates the dynamics of the company's debt and equity.
Analytical breakdowns for brainstorm-cell.com (BCLI)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Total Debt to Capital Brainstorm Cell|BCLI - Long-Term Debt to Equity|Short-Term Debt to Equity BrainStorm Cell Therapeutics|BCLI - Aggregate Debt Obligations|Debts to Book Capitalization Brainstorm Cell Therapeutics, Inc.|BCLI - Company Long-Term Debts|Company Short-Term Debts BrainStorm Cell Therapeutics
Comprehensive company analysis:Brainstorm Cell Therapeutics, Inc.
The stability of Brainstorm Cell (BCLI) depends on the seamless operation of costly cryogenic logistics, which requires high liquidity to minimize supply chain disruption risks. This metric compares the volume of short-term borrowings against equity, determining the business's degree of dependence on external refinancing and its level of financial autonomy. By analyzing changes in the ratio of current liabilities to equity, an investor assesses the company's resilience to creditor pressure and the risk of bankruptcy.
Analysis of competing companies
Biogen Corp - Short-Term Debt to Capital|Current Liabilities to Capital Neurocrine Corp NBIX|Short-Term Debt to Equity Ratio RGC (Regencell Bioscience)|axsome.com - Short-Term Debt to Capital|Short-Term Debt to Equity ACADIA Pharmaceuticals Inc. (ACAD)|XENE: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity VKTX|Supernus Corp (SUPN) - Current Liabilities to Capital|Short-Term Debt to Capital Catalyst Pharmaceuticals|Short-Term Debt to Equity DNLI|Harmony Biosciences Holdings, Inc. (HRMY) - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Biohaven Ltd (BHVN)|Short-Term Debt to Capital AMLX (Amylyx)|Short-Term Debt to Capital Trevi Corp TRVI|Short-Term Debt to Capital PRAX (Praxis Precision Medicines)|AVXL: Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity CeriBell|PRTA (Prothena Biosciences) - Short-Term Debt to Capital Ratio|ALEC: Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient Annexon Biosciences Inc. (ANNX)|Short-Term Debt to Equity Ratio Omeros Corporation|Short-Term Loans to Capital Ratio NGNE (neurogene.com)|ACIU: Short-Term Debt to Equity|Voyager Therapeutics Inc - Current Liabilities to Capital|Short-Term Debt to Equity Neumora Therapeutics Inc (NMRA)|SCLX: Ratio of Short-Term Indebtedness to Capital|TVGN (Tevogen Bio Holdings) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Alpha Cognition Inc.|CGTX - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Inhibikase Therapeutics Inc|Short-Term Debt to Capital SAVA (Cassava)|Short-Term Debt to Equity Ratio assertiotx.com (ASRT)|COYA: Short-Term Debt to Capital|VistaGen Therapeutics, Inc. - Current Liabilities to Capital|OVID - Short-Term Debt to Equity|ABOS: Short-Term Debt to Equity|CervoMed Inc (CRVO) - Short-Term Debt to Equity|Alterity Therapeutics Limited (ATHE) - Short-Term Debt to Equity|Short-Term Debt to Capital Clene Inc|Short-Term Debt to Equity PepGen Corp|Short-Term Debt to Capital JUNS (Jupiter Neurosciences)|Short-Term Debt to Equity Ratio RLMD (Relmada Therapeutics Inc)|Short-Term Debt to Equity Annovis Bio Corp ANVS|Short-Term Debt to Equity Grace Therapeutics Inc GRCE|Short-Term Debt to Capital AIFF (Firefly Neuroscience, Inc)|KLTO: Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity neurosense-tx.com|Reviva Pharmaceuticals Holdings Inc. (RVPH) - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital MTVA (MetaVia Inc.)|Current Liabilities to Capital NeurAxis Inc (NRXS)|Short-Term Debt to Equity Ratio HSDT|Short-Term Debt to Capital PASG (passagebio.com)|Short-Term Debt to Equity Neuphoria Therapeutics|Minerva Neurosciences Inc - Ratio of Short-Term Indebtedness to Capital|ATHA (Athira) - Short-Term Debt to Equity|ADXN - Current Liabilities to Capital|alzamend.com (ALZN) - Short-Term Debt to Capital|CYCN (Cyclerion Therapeutics, Inc.) - Short-Term Debt to Equity|PTIX - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Pasithea|Short-Term Debt to Capital CRGT|Short-Term Debt to Capital Avenue Therapeutics Inc (ATXI)|Short-Term Debt to Capital CARA|chromocell.com - Short-Term Debt to Capital Coefficient|Eliem (ELYM) - Short-Term Debt to Equity|ITCI: Short-Term Debt to Capital Ratio|Longboard Pharma - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient Marinus Pharma|NKGen Biotech, Inc. (NKGN) - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio NRBO|Sage Therapeutics - Short-Term Debt to Equity|Current Liabilities to Capital SNPX (Synaptogenix Inc.)|Short-Term Debt to Equity Trevena, Inc|Vigil Neuroscience Inc. - Ratio of Short-Term Indebtedness to Capital|WENA: Short-Term Debt to Equity|cerevel.com (CERE) - Short-Term Debt to Equity Ratio